<DOC>
	<DOCNO>NCT00837551</DOCNO>
	<brief_summary>WBI-1001 synthetic , new , non-steroid , small molecule develop candidate drug topical , cream treatment inflammatory skin disease . As , affect T-cells inhibition T-cell activity include infiltration process , show direct anti-inflammatory manifestation mouse edema model . This 28 day study ( plus one follow-up week ) patient Atopic Dermatitis , 36 patient treat randomly , BID either 0.5 % , 1.0 % placebo . Blood sample take weekly PK analysis .</brief_summary>
	<brief_title>Phase IIa Study WBI-1001 Cream Atopic Dermatitis</brief_title>
	<detailed_description>A double-blind , single-centered , vehicle-controlled , randomized Phase IIa study WBI-1001 patient mild moderate Atopic Dermatitis ( AD ) . All body area treatable except face , scalp , groin genital area . Cream apply BID 6.00 10.00am 7.00 10.00pm daily 4 week . Blood draw PK analysis take weekly study centre prior morning cream application . Patients return study centre approximately one week later follow-up visit .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>AD diagnosis ( base Hanifin 's criterion ) present minimum 1 % maximum 10 % body surface area ( BSA ) exclude face , groin , scalp genital area . Disease severity index ( EASI ) less 12 , Investigator 's Global Assessment ( IGA ) 23 Day 0 . In good general health free condition might impair evaluation AD . Women child bear potential ( WOCBP ) negative negative serum humanbeta chorionic gonadotropin pregnancy test randomization . WOCBP abstain sex partner use adequate contraceptive precaution duration study . Willing able comply protocol attend study visit . Provide write informed consent form prior initiation study procedure . Had spontaneously improve rapidly deteriorate AD . Had AD lesion hand and/or foot . Had skin disease AD . Had active allergic contact dermatitis nonatopic form dermatitis . Had concomitant medical condition could put patient risk study . Had history neurological/psychiatric disorder could interfere patient 's participation . Had systemic immunomodulatory therapy within 12 week prior baseline visit . Had prolong exposure natural artificial ultraviolet radiation within 4 week baseline visit . Had phototherapy ( include laser ) , photochemotherapy systemic AD therapy within 4 week prior baseline visit . Had topical AD therapy area treat within 2 week prior baseline visit . Had alcohol abuse last 2 year . Had allergic history nonmedical ingredient study cream . Were treated investigational drug within 1 month Day 0 currently participate another trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Non-steroid</keyword>
	<keyword>Small molecule</keyword>
	<keyword>Topical cream</keyword>
	<keyword>Inflammatory disease</keyword>
	<keyword>Skin</keyword>
</DOC>